Novartis buys US-Australian pharma in US$700m deal
30.06.2015 - Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
The Australian drug developer Spinifex Pharma, which is now headquartered in Connecticut (US), is developing a potential first-in-class oral treatment for chronic pain. In particular, neuropathic pain that does not cause central nervous system side effects. Spinifex’ lead candidate, EMA401, a novel angiotensin II type 2 (AT2), could help to treat pain associated with diabetes, shingles (e.g. postherpetic neuralgia (PHN)), chemotherapy and osteoarthritis. Drugs and treatment that target neuropathic pain are urgently needed, as existing treatment is not well tolerated in all individuals and does not relieve pain in some. With the sale, Novartis will continue the development of EMA401 and is also planning to initiate Phase 2b clinical trials in patients with painful diabetic neuropathy (PDN). It also intends to build on these two key indications and pursue a broad peripheral neuropathic pain (PNP) label for EMA401.
Novartis’ US$200m (€180m) deal with the Australian biotech includes further clinical development and regulatory milestones. According to The Sydney Morning Herald, the Swiss giant has committed up to an additional US$500m (€447m) in milestone payments. The upfront payment assures all existing investors a return of at least three times their invested capital. If milestone payments are achieved, which are based on the success of future late-stage clinical trials, it would bring the value of the total deal to US$700m (€626m).
It was the most successful exit in the history of Australia's venture capital industry.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.
12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.
METTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications. more